News & Updates

A recent Singapore meta-analysis of randomized controlled trials (RCT) has found no clear clinical benefit to using convalescent plasma (CP) for patients with the coronavirus disease 2019 (COVID-19), especially in those with severe disease.

A single injection of tocilizumab is enough to weaken systemic inflammation for up to 7 days in patients with the coronavirus disease 2019 (COVID-19), a recent study suggests.

The coverage of influenza vaccination for Medicare beneficiaries remains poor, reports a study, noting missed opportunities despite availability of vaccines with no copayment. In addition, there are still disparities in vaccination uptake by race/ethnicity.

Adults newly diagnosed with COVID-19 in outpatient settings and enrolled in an automated remote monitoring service are less likely to succumb to the disease potentially due to more frequent telemedicine encounters and earlier presentation to the emergency department (ED), a study has shown.

In patients with the coronavirus disease 2019 (COVID-19), hypertension aggravates the risk of cardiac injury and severe disease phenotype, a recent study has found.

The pan-sarbecovirus monoclonal antibody sotrovimab appears to reduce the risk of COVID-19 disease progression in high-risk patients, according to interim results of the phase III COMET-ICE* trial.

Type 2 diabetes (T2D) patients with COVID-19 who have elevated acute-to-chronic (A/C) glycaemic ratio are at increased risk of adverse outcomes, including in-hospital mortality, intensive care unit (ICU) admission, and mechanical ventilation, a study has found.

Vaccines against the coronavirus disease 2019 (COVID-19) induce weaker and more transient immune responses in liver transplant recipients, those with cirrhosis, or those with chronic liver disease (CLD), according to a study presented at The Liver Meeting Digital Experience 2021 by the American Association for the Study of Liver Diseases (AASLD 2021).